[go: up one dir, main page]

WO2006033943A3 - Modulateurs de kinases a base de pyrazole et leurs procedes d'utilisation - Google Patents

Modulateurs de kinases a base de pyrazole et leurs procedes d'utilisation Download PDF

Info

Publication number
WO2006033943A3
WO2006033943A3 PCT/US2005/032839 US2005032839W WO2006033943A3 WO 2006033943 A3 WO2006033943 A3 WO 2006033943A3 US 2005032839 W US2005032839 W US 2005032839W WO 2006033943 A3 WO2006033943 A3 WO 2006033943A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compounds
kinase modulators
pyrazole
pyrazole kinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/032839
Other languages
English (en)
Other versions
WO2006033943A2 (fr
Inventor
Tae-Gon Baik
Chris A Buhr
Sunghoon Ma
John M Nuss
Zerom Tesfai
Longcheng Wang
Bryan K S Yeung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exelixis Inc
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Priority to JP2007532443A priority Critical patent/JP5063351B2/ja
Priority to CA002579313A priority patent/CA2579313A1/fr
Priority to US11/575,411 priority patent/US8710038B2/en
Priority to AU2005287170A priority patent/AU2005287170B2/en
Priority to EP05796701A priority patent/EP1797072A4/fr
Publication of WO2006033943A2 publication Critical patent/WO2006033943A2/fr
Publication of WO2006033943A3 publication Critical patent/WO2006033943A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention se rapporte à des composés destinés à moduler l'activité enzymatique des protéines kinases afin de moduler des activités cellulaires telles que la prolifération, la différenciation, la mort cellulaire programmée, la migration et la chimio-invasion. Les composés selon l'invention inhibent, régulent et/ou modulent les kinases. Dans un aspect, l'invention a également trait à des procédés d'utilisation des composés et de compositions pharmaceutiques à base de ces derniers pour traiter des maladies et des troubles liés aux kinases.
PCT/US2005/032839 2004-09-17 2005-09-15 Modulateurs de kinases a base de pyrazole et leurs procedes d'utilisation Ceased WO2006033943A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2007532443A JP5063351B2 (ja) 2004-09-17 2005-09-15 ピラゾールキナーゼモジュレーターおよび使用方法
CA002579313A CA2579313A1 (fr) 2004-09-17 2005-09-15 Modulateurs de kinases a base de pyrazole et leurs procedes d'utilisation en tant qu'inhibiteurs de la kinase ckit ou fit3
US11/575,411 US8710038B2 (en) 2004-09-17 2005-09-15 Pyrazole kinase modulators and methods of use
AU2005287170A AU2005287170B2 (en) 2004-09-17 2005-09-15 Pyrazole kinase modulators and methods of use
EP05796701A EP1797072A4 (fr) 2004-09-17 2005-09-15 Modulateurs de kinases a base de pyrazole et leurs procedes d'utilisation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61068904P 2004-09-17 2004-09-17
US60/610,689 2004-09-17

Publications (2)

Publication Number Publication Date
WO2006033943A2 WO2006033943A2 (fr) 2006-03-30
WO2006033943A3 true WO2006033943A3 (fr) 2006-06-01

Family

ID=36090487

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/032839 Ceased WO2006033943A2 (fr) 2004-09-17 2005-09-15 Modulateurs de kinases a base de pyrazole et leurs procedes d'utilisation

Country Status (6)

Country Link
US (1) US8710038B2 (fr)
EP (1) EP1797072A4 (fr)
JP (2) JP5063351B2 (fr)
AU (1) AU2005287170B2 (fr)
CA (1) CA2579313A1 (fr)
WO (1) WO2006033943A2 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005286648A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
CA2580857A1 (fr) 2004-09-20 2006-09-28 Xenon Pharmaceuticals Inc. Derives heterocycliques et leur utilisation en tant qu'agents therapeutiques
MX2007015216A (es) 2005-06-03 2008-02-22 Xenon Pharmaceuticals Inc Derivados de aminotiazol y sus usos como agentes terapeuticos.
CN101058561B (zh) * 2006-04-19 2011-01-26 苏州爱斯鹏药物研发有限责任公司 用于抑制蛋白激酶的二苯脲衍生物及其组合物和用途
CA2724430A1 (fr) * 2008-05-19 2009-11-26 Schering Corporation Composes heterocycliques en tant qu'inhibiteurs du facteur ixa
EP2330894B8 (fr) 2008-09-03 2017-04-19 BioMarin Pharmaceutical Inc. Compositions comprenant des dérivés d acide 6-aminohexanoïque utilisées comme inhibiteurs de hdac
US8329757B2 (en) * 2008-10-14 2012-12-11 Charlesson, Llc Curcumin analog compositions and related methods
KR101756495B1 (ko) 2010-03-11 2017-07-10 다이닛본 스미토모 세이야꾸 가부시끼가이샤 Ｎ-아실 시클릭 아민 유도체 또는 이의 의약상 허용되는 염
ES2555260T3 (es) * 2010-06-15 2015-12-30 Bayer Intellectual Property Gmbh Derivados de diamida de ácido antranílico
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
CA3061239A1 (fr) 2011-02-28 2012-09-07 Biomarin Pharmaceutical Inc. Inhibiteurs de l'histone deacetylase
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US9399635B2 (en) 2011-04-11 2016-07-26 Green Tech Co., Ltd. Pyrazole derivative
US9199975B2 (en) 2011-09-30 2015-12-01 Asana Biosciences, Llc Biaryl imidazole derivatives for regulating CYP17
US8809372B2 (en) 2011-09-30 2014-08-19 Asana Biosciences, Llc Pyridine derivatives
HK1213253A1 (en) 2012-10-10 2016-06-30 Green Tech Co., Ltd. Novel pyrazole derivatives
PL403149A1 (pl) * 2013-03-14 2014-09-15 Celon Pharma Spółka Akcyjna Nowe związki pochodne pirazolilobenzo[d]imidazolu
CN105121415B (zh) 2013-03-15 2018-10-12 生物马林药物股份有限公司 Hdac抑制剂
EP2944635B1 (fr) * 2014-05-15 2018-11-28 Council of Scientific & Industrial Research Conjugués de benzimidazole liés au pyrazole et leur procédé de préparation
GB201506658D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
GB201506660D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
EP3643705A1 (fr) * 2018-10-24 2020-04-29 Basf Se Composés pesticides
JP7742175B2 (ja) * 2021-03-03 2025-09-19 白鳥製薬株式会社 ピラゾール化合物の製造方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE923028C (de) * 1952-04-02 1955-01-31 Basf Ag Verfahren zur Herstellung von Kuepenfarbstoffen
US3948937A (en) * 1972-02-29 1976-04-06 E. I. Du Pont De Nemours And Company Pyrazole plant growth regulants
ZA744908B (en) * 1973-09-17 1975-08-27 American Cyanamid Co Catalytic dehydrogenation process for the preparation of 3,5-disubstituted pyrazoles
GB1484615A (en) * 1974-11-23 1977-09-01 Lepetit Spa Tricyclic n-containing derivatives
US4014896A (en) * 1975-02-12 1977-03-29 American Cyanamid Company Catalytic dehydrogenation process for the preparation of 3,4,5-trisubstituted pyrazoles
IE59813B1 (en) * 1986-05-09 1994-04-06 Warner Lambert Co Styryl pyrazoles, isoxazoles and analogs thereof having activity as 5-lipoxy-genase inhibitors and pharmaceutical compositions containing them
US4877881A (en) * 1987-04-06 1989-10-31 Warner-Lambert Company Process of preparing pyrazoles, isoxazoles and analogs thereof having activity as 5-lipoxygenase inhibitors
DE3903993A1 (de) * 1989-02-10 1990-08-16 Basf Ag Diarylsubstituierte heterocyclische verbindungen, ihre herstellung und arzneimittel daraus
JPH04124178A (ja) 1990-09-12 1992-04-24 Sds Biotech Kk 複素環式化合物および該化合物を含有する除草剤
EP0628563B1 (fr) * 1993-06-08 1999-03-03 BASF Aktiengesellschaft Procédé pour la préparation de pyrazoles N-substituées
US5783593A (en) * 1993-11-04 1998-07-21 Abbott Laboratories Inhibitors of squalene synthetase and protein farnesyltransferase
DE19500838A1 (de) * 1995-01-13 1996-07-18 Basf Ag Verfahren zur Herstellung von 3,5-Diarylpyrazolen
US6291505B1 (en) 1998-08-07 2001-09-18 Chiron Corporation Estrogen receptor modulators
AU1199600A (en) 1998-10-02 2000-04-26 Board Of Trustees Of The University Of Illinois, The Estrogen receptor ligands
DE19904397A1 (de) 1999-02-04 2000-08-10 Bayer Ag Verwendung von Pyrazol-Carbonsäureamiden
IL150368A0 (en) * 1999-12-23 2002-12-01 Nitromed Inc Nitrosated and nitrosylated cyclooxygenase-2-inhibitors, compositions and methods of use
JP4371295B2 (ja) * 2000-05-19 2009-11-25 メルク セローノ ソシエテ アノニム 医薬として活性な化合物およびその使用方法
CA2439593C (fr) * 2001-04-05 2010-02-09 Torrent Pharmaceuticals Ltd. Composes heterocycliques pour des complications vasculaires diabetiques et liees au vieillissement
MXPA03011196A (es) 2001-06-08 2004-10-28 Cytovia Inc 3-aril-5-aril-[1,2,4]-oxadiazoles sustituidos y analogos.
FR2831536A1 (fr) * 2001-10-26 2003-05-02 Aventis Pharma Sa Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr
CA2465247C (fr) 2001-10-26 2010-05-18 Aventis Pharmaceuticals Inc. Benzimidazoles et analogues et leur utilisation comme inhibiteurs de proteines kinases
JP2005162612A (ja) * 2002-01-09 2005-06-23 Ajinomoto Co Inc アシルスルホンアミド誘導体
US6790979B2 (en) 2002-04-17 2004-09-14 University Of North Carolina At Chapel Hill Curcumin analogues and uses thereof
NI200300045A (es) * 2002-04-26 2005-07-08 Pfizer Prod Inc Inhibidores de triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa.
WO2003105751A2 (fr) * 2002-06-17 2003-12-24 Ho-Jeong Kwon Nouveaux derives de curcumine
EP1601657A1 (fr) * 2003-03-12 2005-12-07 Vertex Pharmaceuticals Incorporated Pyrazoles, modulateurs de transporteurs de cassettes de liaison a l'atp
US7115642B2 (en) 2003-05-02 2006-10-03 Rigel Pharmaceuticals, Inc. Substituted diphenyl isoxazoles, pyrazoles and oxadiazoles useful for treating HCV infection
GB0326601D0 (en) 2003-11-14 2003-12-17 Novartis Ag Organic compounds
WO2005095338A1 (fr) * 2004-03-30 2005-10-13 Takeda Pharmaceutical Company Limited Dérivés de l’acide alkoxyphénylpropanoïque
WO2005094823A1 (fr) 2004-03-30 2005-10-13 Kyowa Hakko Kogyo Co., Ltd. INHIBITEUR DE Flt-3

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TANITAME A. ET AL: "Synthesis and Antibacterial Activity of a Novel Series of Potent DNA Gyrase Inhibitors. Pyrazole Derivatives", JOURNAL OF MEDICINAL CHEMISTRY, vol. 47, no. 14, 1 July 2004 (2004-07-01), pages 3693 - 3696, XP002996150 *

Also Published As

Publication number Publication date
JP2008513464A (ja) 2008-05-01
WO2006033943A2 (fr) 2006-03-30
EP1797072A4 (fr) 2009-09-09
CA2579313A1 (fr) 2006-03-30
AU2005287170A1 (en) 2006-03-30
AU2005287170B2 (en) 2012-03-29
US8710038B2 (en) 2014-04-29
US20070293507A1 (en) 2007-12-20
JP5063351B2 (ja) 2012-10-31
JP2012153720A (ja) 2012-08-16
EP1797072A2 (fr) 2007-06-20

Similar Documents

Publication Publication Date Title
WO2004092196A3 (fr) Modulateurs de tie-2 et procedes d'utilisation
WO2006033943A3 (fr) Modulateurs de kinases a base de pyrazole et leurs procedes d'utilisation
WO2004091480A3 (fr) Modulateurs de tie-2 et procedes d'utilisation
WO2005117909A3 (fr) Modulateurs des proteines kinases et leurs methodes d'utilisation
WO2005112932A3 (fr) Modulateurs de raf et methodes d'utilisation
WO2005020921A3 (fr) Modulateurs c-kit et leurs procedes d'utilisation
WO2005040355A3 (fr) Modulateurs de kinases tao et leurs methodes d'utilisation
WO2005039506A3 (fr) Modulateurs des p70s6 kinases et procede d'utilisation
WO2003093297A3 (fr) Modulateurs de proteine kinase et procedes d'utilisation
WO2005030140A3 (fr) Modulateurs de c-met et procede d'utilisation
WO2006014325A3 (fr) Modulateurs de c-met et leur methode d'utilisation
ATE543821T1 (de) Ä1h-pyrazoloä3,4-düpyrimidin-4-ylü-piperidin- oder piperazinverbindungen als serin-threonin- kinasemodulatoren (p70s6k, atk1 und atk2) zur behandlung von immunologischen, entzündlichen und proliferativen erkrankungen
WO2004083235A3 (fr) Modulateurs de tie-2 et procedes d'utilisation
MY148468A (en) Compounds and methods for kinase modulation, and indications therefor
MX2009006688A (es) Compuestos y metodos para modulacion de cinasas, e indicaciones para ello.
AU2008266182A8 (en) Metabolites of the janus kinase inhibitor (r)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl)-3- cyclopentylpropanenitrile
UA95244C2 (ru) Соединения и способ модулирования активности киназ, и показания для их применения
WO2007030680A3 (fr) Derives de triazole utiles comme inhibiteurs d'axl
WO2008063888A3 (fr) Composés modulant l'activité de c-fms et/ou de c-kit et utilisations associées
WO2004089286A3 (fr) Nouveaux composes et compositions utilises comme inhibiteurs de la proteine kinase
WO2009114870A3 (fr) Inhibiteurs de kinases, et procédés d’utilisation associés
EP2476679A3 (fr) Triazoles substitués utilisés comme inhibiteurs AXL
WO2004050681A3 (fr) Modulateurs de kinase
WO2006091701A3 (fr) Methodes et compositions permettant de moduler la mort cellulaire a l'aide de kinases ou de phosphatases controlant la survie cellulaire ou l'apoptose
WO2007056056A3 (fr) Entites et compositions chimiques et methodes associees

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005796701

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2005287170

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2579313

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007532443

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 11575411

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2005287170

Country of ref document: AU

Date of ref document: 20050915

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005287170

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005796701

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11575411

Country of ref document: US